- Home
- APVO vs CTXR Comparison
APVO vs CTXR Comparison
Compare APVO & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- CTXR
- Stock Information
- Founded
- APVO 2016
- CTXR 2007
- Country
- APVO United States
- CTXR United States
- Employees
- APVO N/A
- CTXR N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- CTXR Health Care
- Exchange
- APVO Nasdaq
- CTXR Nasdaq
- Market Cap
- APVO 21.7M
- CTXR 19.8M
- IPO Year
- APVO N/A
- CTXR N/A
- Fundamental
- Price
- APVO $1.09
- CTXR $1.01
- Analyst Decision
- APVO
- CTXR Buy
- Analyst Count
- APVO 0
- CTXR 2
- Target Price
- APVO N/A
- CTXR $6.00
- AVG Volume (30 Days)
- APVO 757.7K
- CTXR 445.1K
- Earning Date
- APVO 11-06-2025
- CTXR 12-26-2025
- Dividend Yield
- APVO N/A
- CTXR N/A
- EPS Growth
- APVO N/A
- CTXR N/A
- EPS
- APVO N/A
- CTXR N/A
- Revenue
- APVO N/A
- CTXR N/A
- Revenue This Year
- APVO N/A
- CTXR N/A
- Revenue Next Year
- APVO N/A
- CTXR $731.60
- P/E Ratio
- APVO N/A
- CTXR N/A
- Revenue Growth
- APVO N/A
- CTXR N/A
- 52 Week Low
- APVO $1.07
- CTXR $0.65
- 52 Week High
- APVO $298.00
- CTXR $5.95
- Technical
- Relative Strength Index (RSI)
- APVO 27.92
- CTXR 35.99
- Support Level
- APVO $1.39
- CTXR $0.92
- Resistance Level
- APVO $1.54
- CTXR $1.10
- Average True Range (ATR)
- APVO 0.09
- CTXR 0.11
- MACD
- APVO -0.03
- CTXR -0.04
- Stochastic Oscillator
- APVO 3.06
- CTXR 9.21
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.